Protein AMN1 homolog (AMN1)

**Protein AMN1 homolog (AMN1)** is an atypical F-box-containing protein in budding yeast that acts as an antagonist of the mitotic exit network (MEN). It downregulates the MEN by binding to and inhibiting the GTPase Tem1 through two independent mechanisms: promoting Tem1’s removal from spindle pole bodies (SPBs) followed by nuclear import, and facilitating its proteolysis via the Skp, Cullin and F-box-containing (SCF) ubiquitin ligase. AMN1 is required to turn off MEN signaling after mitosis and thereby ensures proper temporal coordination of cell-cycle exit, cytokinesis, and subsequent cell separation. Additionally, AMN1 inhibits the transcription factor Ace2, thereby repressing genes required for post-mitotic separation of mother and daughter cells, which can lead to a cell clumping phenotype. AMN1's primary biological roles are specific to yeast and have no established relevance as a drug target or biomarker in human disease[1][2]. **Interpretation and caveats**: - AMN1 is not a mammalian (human/animal) therapeutic target, receptor, enzyme, transporter, or druggable protein, but a yeast regulatory protein; hence, `is_target` is false and `is_incorrect` is true for use in typical pharmaceutical/therapeutic target contexts. - There are no known therapeutic drugs, disease roles in humans, or established biomarker or safety implications for this target[1][2]. - Its main usage is in basic research, primarily in studies of cell cycle regulation in budding yeast.

Other names

Antagonist of mitotic exit network 1 homologAmn1protein Amn1 homolog